Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Enhancement of nerve regeneration following neonatal peripheral nerve injury
EF 2013-14
Résumé
Obstetrical brachial plexus palsy (OBPP) occurs when nerves are stretched and sometimes ruptured during delivery. OBPP occurs in approximately 1 in every 500 live births, and more than 25% of infants with this condition are left with permanent paralysis, numbness or chronic pain for the duration of their lives. At such a young age, neurons are susceptible to death after nerve injury. Without neurons, recovery of the nervous system is limited leaving children with permanent weakness and numbness. Studies in neonatal rats have shown that following nerve injury over 60% of neurons die and similar findings have been observed in higher mammals, including monkeys, and even a human case. Presently, management of peripheral nerve injuries is exclusively surgical. Pharmacologic protection from neuronal cell death would represent a major treatment development. Preliminary studies have demonstrated that a new chemical compound, P7C3, protects neurons following peripheral nerve injury and improves recovery. P7C3 has also been shown to protect neurons in animal models of Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and traumatic brain injury. The anti-oxidants N-acetyl cysteine (NAC) and acetyl-L-carnitine (ALC) have also demonstrated neuronal protection in adult models of peripheral nerve injury, but they have not been investigated in pediatric nerve injuries where they may be most beneficial.
The objective of this research is to investigate the potential of P7C3, NAC and ALC to protect neurons after neonatal nerve injury and improve nerve regeneration and recovery. We expect that P7C3, NAC and ALC will increase neuronal survival after nerve injury and will improve nerve regeneration and recovery. Experiments will be carried out in a rat-model of obstetrical brachial plexus injury in which rats will have their sciatic nerve surgically injured after birth. They will then be treated with daily injections of P7C3, NAC or ALC for two weeks. At one month of age, the number of surviving neurons and the number of regenerated axons will be counted and compared to uninjured and untreated rats. Muscle strength and footpad sensation will be recorded to assess how rats have recovered after injury, and several locomotor tests will be utilized to assess whether the resulting innervation can be used in a coordinated fashion by the rats. All techniques used in this study are established in Dr. Borschel’s laboratory and no model development is required.
This research proposal outlines a strategy to investigate several pharmaceutical agents that have a high potential to improve outcomes in children with nerve injuries. Neonatal peripheral nerve injuries can be devastating because children live with the effects of injury for their entire lives. Improving survival of neurons after injury may provide children with improved capacity to repair the nervous system. This research will build on the lab’s previous work with P7C3 and will be the first neonatal investigations with NAC and ALC. NAC and ALC have a documented history of safe clinical use for other indications, making future clinical translation feasible. If positive, this research would provide the foundation for subsequent clinical trials.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311861
Name
Catapano Joseph
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancement of nerve regeneration following neonatal peripheral nerve injury
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acetyl-L-Carnitine; N-Acetyl Cysteine; Nerve Injury; Nerve Regeneration; P7c3
Abstract
Obstetrical brachial plexus palsy (OBPP) occurs when nerves are stretched and sometimes ruptured during delivery. OBPP occurs in approximately 1 in every 500 live births, and more than 25% of infants with this condition are left with permanent paralysis, numbness or chronic pain for the duration of their lives. At such a young age, neurons are susceptible to death after nerve injury. Without neurons, recovery of the nervous system is limited leaving children with permanent weakness and numbness. Studies in neonatal rats have shown that following nerve injury over 60% of neurons die and similar findings have been observed in higher mammals, including monkeys, and even a human case. Presently, management of peripheral nerve injuries is exclusively surgical. Pharmacologic protection from neuronal cell death would represent a major treatment development. Preliminary studies have demonstrated that a new chemical compound, P7C3, protects neurons following peripheral nerve injury and improves recovery. P7C3 has also been shown to protect neurons in animal models of Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and traumatic brain injury. The anti-oxidants N-acetyl cysteine (NAC) and acetyl-L-carnitine (ALC) have also demonstrated neuronal protection in adult models of peripheral nerve injury, but they have not been investigated in pediatric nerve injuries where they may be most beneficial.
The objective of this research is to investigate the potential of P7C3, NAC and ALC to protect neurons after neonatal nerve injury and improve nerve regeneration and recovery. We expect that P7C3, NAC and ALC will increase neuronal survival after nerve injury and will improve nerve regeneration and recovery. Experiments will be carried out in a rat-model of obstetrical brachial plexus injury in which rats will have their sciatic nerve surgically injured after birth. They will then be treated with daily injections of P7C3, NAC or ALC for two weeks. At one month of age, the number of surviving neurons and the number of regenerated axons will be counted and compared to uninjured and untreated rats. Muscle strength and footpad sensation will be recorded to assess how rats have recovered after injury, and several locomotor tests will be utilized to assess whether the resulting innervation can be used in a coordinated fashion by the rats. All techniques used in this study are established in Dr. Borschel’s laboratory and no model development is required.
This research proposal outlines a strategy to investigate several pharmaceutical agents that have a high potential to improve outcomes in children with nerve injuries. Neonatal peripheral nerve injuries can be devastating because children live with the effects of injury for their entire lives. Improving survival of neurons after injury may provide children with improved capacity to repair the nervous system. This research will build on the lab’s previous work with P7C3 and will be the first neonatal investigations with NAC and ALC. NAC and ALC have a documented history of safe clinical use for other indications, making future clinical translation feasible. If positive, this research would provide the foundation for subsequent clinical trials.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Catapano, Joseph
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~